INKT Stock Price, MiNK Therapeutics, Inc. Quote, Chart

Market Summary

USD0.930.00

Delayedas of 08 May 2024, 01:32 pm

0.00%

INKT Stock Price

View Fullscreen

INKT RSI Chart

INKT Valuation

Market Cap

32.3M

Price/Earnings (Trailing)

-1.44

Price/Free Cashflow

-2.04

INKT Price/Earnings (Trailing)

INKT Profitability

Return on Equity

124.38%

Return on Assets

-493.33%

Free Cashflow Yield

-49.07%

INKT Fundamentals

INKT Earnings

Earnings (TTM)

-22.5M

Earnings Growth (Yr)

29.75%

Earnings Growth (Qtr)

-6.69%

Breaking Down INKT Revenue

52 Week Range

0.923.34

(Low)(High)

Last 7 days

-6.1%

Last 30 days

-40.4%

Last 90 days

10.7%

Trailing 12 Months

-48.9%

How does INKT drawdown profile look like?

INKT Financial Health

Current Ratio

0.32

INKT Investor Care

Shares Dilution (1Y)

2.32%

Diluted EPS (TTM)

-0.65

Tracking the Latest Insider Buys and Sells of MiNK Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	corvese brian	acquired	17,875	0.95	18,816	-
Mar 01, 2024	ryan barbara	acquired	17,750	0.95	18,685	-
Mar 01, 2024	wiinberg ulf	acquired	15,000	0.95	15,790	-
Mar 01, 2024	behner peter	acquired	15,375	0.95	16,185	-
Dec 01, 2023	corvese brian	acquired	17,875	1.04	17,188	-
Dec 01, 2023	wiinberg ulf	acquired	15,001	1.04	14,424	-
Dec 01, 2023	ryan barbara	acquired	17,750	1.04	17,068	-
Dec 01, 2023	behner peter	acquired	15,375	1.04	14,784	-
Oct 16, 2023	agenus inc	bought	471	1.0992	429	-
Oct 13, 2023	agenus inc	bought	21,310	1.1	19,373	-

Which funds bought or sold INKT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-1.00	-	-%
May 06, 2024	HighTower Advisors, LLC	reduced	-0.12	-6,000	43,000	-%
May 03, 2024	SIGNATUREFD, LLC	sold off	-100	-14.00	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Key Financial Inc	unchanged	-	-	46.00	-%
Apr 30, 2024	Longbow Finance SA	unchanged	-	-26,950	151,383	0.01%
Apr 26, 2024	LifeSteps Financial, Inc.	new	-	25.00	25.00	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-1.00	2.00	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	-28.00	154	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	-	5.00	-%

Are Funds Buying or Selling INKT?

Are funds buying INKT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INKT

No. of Funds

Unveiling MiNK Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armen garo h	9.68%	3,514,320	SC 13D
May 26, 2023	agenus inc	62.5%	21,522,157	SC 13D/A
May 03, 2023	agenus inc	62%	21,344,685	SC 13D/A
Feb 14, 2022	armen garo h	7.82%	2,616,882	SC 13G

Recent SEC filings of MiNK Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 29, 2024	8-K	Current Report
Feb 14, 2024	SC 13D	13D - Major Acquisition

Peers (Alternatives to MiNK Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

MiNK Therapeutics, Inc. News

Latest updates

MiNK Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-39.0%	5.00	7.00	12.00	17.00	21.00	25.00	31.00	36.00	40.00	4.00	5.00
Current Assets	-44.4%	4.00	6.00	11.00	16.00	20.00	24.00	30.00	35.00	40.00	3.00	4.00
Cash Equivalents	-47.4%	3.00	6.00	11.00	15.00	20.00	24.00	30.00	35.00	39.00	1.00	3.00
Net PPE	-3.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Current Liabilities	9.7%	11.00	10.00	11.00	11.00	13.00	18.00	17.00	19.00	16.00	81.00	14.00
Shareholder's Equity	-Infinity%	-18.06	-	-	-	-0.40	7.00	14.00	17.00	24.00	-	-
Retained Earnings	-4.3%	-133	-127	-122	-116	-110	-103	-96.80	-90.72	-82.95	-77.18	-52.74
Additional Paid-In Capital	1.0%	116	115	114	113	111	110	109	108	107	1.00	0.00
Accumulated Depreciation	14.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Shares Outstanding	0.9%	35.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	33.00	24.00	24.00
Float	-	-	-	21.00	-	-	-	7.00	-	-	43.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	27.9%	-3,035	-4,209	-4,151	-4,366	-4,430	-5,614	-4,625	-4,196	-1,702	-3,495	-3,420	-4,208	-	-
Share Based Compensation	17.3%	1,102	939	898	921	668	773	801	786	667	387	407	283	-	-
Cashflow From Investing	100.0%	-	-23.04	-37.02	-13.50	-127	-59.79	-	-	277*	-111	-97.92	-39.52	-	-
Cashflow From Financing	-100.1%	-2*	3.00	-75.70	-334	111*	494*	-156	689*	39,797	2,783	4,352	2,324	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INKT Income Statement

2023-12-31

Consolidated Statement of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 15,489,997	$ 23,115,123
General and administrative	7,431,108	7,834,155
Operating loss	(22,921,105)	(30,949,278)
Other income (expense), net:
Interest Income (Expense), Net	463,256	253,323
Other income (loss), net	(10)	2,704,743
Net loss	$ (22,457,859)	$ (27,991,212)
Per common share data:
Basic net loss per common share	$ (0.65)	$ (0.83)
Diluted net loss per common share	$ (0.65)	$ (0.83)
Weighted average number of common shares outstanding, basic	34,359,945	33,672,927
Weighted average number of common shares outstanding, diluted	34,359,945	33,672,927
Other comprehensive gain (loss)
Foreign currency translation gain (loss)	$ (138,479)	$ 332,801
Comprehensive loss	$ (22,596,338)	$ (27,658,411)

INKT Balance Sheet

2023-12-31

Consolidated Balance Sheet - USD ($)	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 3,367,229	$ 19,635,725
Prepaid expenses	53,111	298,667
Other current assets	177,964	470,300
Total current assets	3,598,304	20,404,692
Equipment, net of accumulated depreciation of $495,638 and $283,682 as of December 31, 2023 and 2022, respectively	953,977	1,066,910
Total assets	4,552,281	21,471,602
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	3,911,973	5,823,000
Accrued liabilities	5,037,361	4,238,555
Other current liabilities	2,453,251	2,621,611
Total current liabilities	11,402,585	12,683,166
Other long-term liabilities	48,072	108,500
Due To Related Party	11,157,073	9,081,239
Commitments and contingencies
Stockholders' deficit
Common stock, par value $0.00001 per share, 150,000,000 shares authorized, 34,599,119 and 33,856,428 shares issued and outstanding as of December 31, 2023 and 2022, respectively	346	339
Additional paid-in capital	115,772,085	110,829,900
Accumulated other comprehensive loss	(430,947)	(292,468)
Accumulated deficit	(133,396,933)	(110,939,074)
Total stockholders' deficit	(18,055,449)	(401,303)
Total liabilities and stockholders' deficit	$ 4,552,281	$ 21,471,602

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

CEO	Dr. Jennifer S. Buell Ph.D.
WEBSITE	https://minktherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	37

MiNK Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for MiNK Therapeutics, Inc.? What does INKT stand for in stocks?

INKT is the stock ticker symbol of MiNK Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiNK Therapeutics, Inc. (INKT)?

As of Tue May 07 2024, market cap of MiNK Therapeutics, Inc. is 32.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INKT stock?

You can check INKT's fair value in chart for subscribers.

What is the fair value of INKT stock?

You can check INKT's fair value in chart for subscribers. The fair value of MiNK Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MiNK Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INKT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MiNK Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether INKT is over valued or under valued. Whether MiNK Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact MiNK Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INKT.